Internet Archive Scholar

CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies

Evgeny Klyuchnikov, Jean El-Cheikh, Andreas Sputtek, Michael Lioznov, Boris Calmels, Sabine Furst, Christian Chabannon, Roberto Crocchiolo, Claude Lemarié, Catherine Faucher, Ulrike Bacher, Haefaa Alchalby (+6 others)
2014 Biology of Blood and Marrow Transplantation  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (333.0 kB)
https://web.archive.org/web/20170927154914/http://publisher-connector.core.ac.uk/resourcesync/data/elsevier/pdf/55a/aHR0cDovL2FwaS5lbHNldmllci5jb20vY29udGVudC9hcnRpY2xlL3BpaS9zMTA4Mzg3OTExMzAwNTcxNQ%3D%3D.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL. The file type is application/pdf.

We retrospectively analyzed outcomes of a CD34 þ -selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils 1.5 x 10 9 /L, and/or platelets 30 x 10 9 /L, and/or hemoglobin 8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34 þ and CD3 þ cells were 3.4 x 10 6 /kg (.96 to 8.30) and 9 x 10 3 /kg body weight
more » ... range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P ¼ .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3 þ cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation. Ó
doi:10.1016/j.bbmt.2013.11.034 pmid:24321747 fatcat:ur3pf5x2s5byxkqrxyvhrwpeg4
Open Access
Citation

Evgeny Klyuchnikov, Jean El-Cheikh, Andreas Sputtek, Michael Lioznov, Boris Calmels, Sabine Furst, Christian Chabannon, Roberto Crocchiolo, Claude Lemarié, Catherine Faucher, Ulrike Bacher, Haefaa Alchalby, Thomas Stübig, Christine Wolschke, Francis Ayuk, Marie-Luise Reckhaus, Didier Blaise, Nicolaus Kröger. "CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies." Biology of Blood and Marrow Transplantation 20.3 (2014) 382-386